A PHASE 1/2 STUDY OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20+ TUMORS, RITUXIMAB IN PATIENTS WITH RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS-THE P[R]EBEN STUDY